Biomarkers: The Indispensable Healthcare Tools

Abstract

Biomarkers have reformed the game of diagnosis and prognosis of diseased conditions over the last 50 years. They have become powerful tools to classify patients according to their risk of disease progression, severity of the disease and guide drug therapy. The Food and Drug Administration (FDA) currently listed over 39 biomarkers that may be used as outcomes for FDA approved therapeutics. Moreover, in association with NIH, FDA has published the B.E.S.T. resource to establish uniformity
and harmonization categorically for the discussion of biomarkers. This article briefly touches upon this harmonization and
uniformity brought in by FDA and NIH in terms of discussions related to biomarkers for the ease of everyone’s understanding
and information, its Biomarker Qualifying Programme, what are the Top 10 diseases causing deaths worldwide according to
WHO and which biomarkers are used for their diagnosis and prognosis. Briefly, this article captures how far we have progressed in these 50 years and how elusive and distant the dream of gold standard biomarkers still is.

Conflict of Interest: None declared

Sources of Support: None declared